Mersana Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Mersana Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2016 to Q3 2024.
  • Mersana Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $4.03M, a 0.65% increase year-over-year.
  • Mersana Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $17.2M, a 23.1% decline year-over-year.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21.1M, a 1.79% decline from 2022.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21.5M, a 16.9% increase from 2021.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $18.4M, a 157% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $17.2M $4.03M +$26K +0.65% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $17.2M $4.43M -$2.22M -33.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $19.4M $4.66M -$1.75M -27.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $21.1M $4.09M -$1.23M -23.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $22.4M $4M -$1.37M -25.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $23.7M $6.64M +$1.3M +24.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $22.4M $6.41M +$922K +16.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $21.5M $5.31M +$454K +9.34% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $21.1M $5.38M +$447K +9.07% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $20.6M $5.35M +$766K +16.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $19.9M $5.49M +$1.45M +35.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $18.4M $4.86M +$2.87M +144% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $15.5M $4.93M +$3.01M +157% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $12.5M $4.58M +$2.93M +177% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $9.6M $4.04M +$2.43M +151% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $7.17M $1.99M +$727K +57.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $6.45M $1.92M +$633K +49.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $5.81M $1.66M +$495K +42.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $5.32M $1.61M +$445K +38.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $4.87M $1.26M +$132K +11.7% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $4.74M $1.29M +$232K +22% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $4.51M $1.16M +$205K +21.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $4.3M $1.16M +$419K +56.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $3.88M $1.13M +$697K +161% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $3.19M $1.05M +$680K +182% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $2.51M $956K +$604K +172% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $1.9M $745K +$481K +182% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $1.42M $433K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-28
Q3 2017 $373K +$177K +90.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $352K +$221K +169% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $264K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q3 2016 $196K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $131K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.